Oppenheimer Maintains Fulcrum Therapeutics (FULC) Outperform Recommendation
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Fintel reports that on May 16, 2023, Oppenheimer maintained coverage of Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform recommendation.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-508485059-2326445892774fb095812e4887918c47.jpg "How to Get a Personal Loan")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1680602432-fcce311299f54fd2862f17efc78d0911.jpg "Top 5 Ways Terrorism Impacts the Economy")
